Evaluate Safety of Adipose Derived Mesenchymal Stem Cell Transplantation for Type 1 Diabetes Treatment

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

May 4, 2021

Primary Completion Date

December 30, 2024

Study Completion Date

December 30, 2024

Conditions
Type 1 Diabetes
Interventions
COMBINATION_PRODUCT

adipose-derived messenchymal stem cell

Collaborative research program between Vinmec Research Institute of Stem Cell and Gene Technology with the National Yang-Ming University in Taiwan The adipose mesenchymal stem cell line (GXIPC1) was collected from healthy donors who have screened for infectious diseases and then multiplied in large numbers. These products were produced following the GMP laboratory system and approved by Taiwan FDA for preclinical and clinical trials with completed certificates

Trial Locations (1)

10000

Vinmec Research Institute of Stem Cell and Gene Technology, Hanoi

All Listed Sponsors
collaborator

Gwoxi Stem cell applied technology Company

UNKNOWN

lead

Vinmec Research Institute of Stem Cell and Gene Technology

OTHER